TEXT {#s1}
====

Doravirine (DOR) is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) that has been approved for the treatment of HIV-1 at a dosage of 100 mg once daily. DOR (100 mg) is available as a single-entity tablet ([@B1]) and as a fixed-dose combination tablet with lamivudine (3TC) (300 mg) and tenofovir disoproxil fumarate (TDF) (300 mg) ([@B2]). The efficacy and safety of DOR in treatment-naive adults with HIV-1 were demonstrated in two phase 3 clinical trials, DRIVE-FORWARD ([@B3]) and DRIVE-AHEAD ([@B4]). More recently, maintenance of HIV-1 suppression was demonstrated in adults who switched from a stable antiretroviral regimen to DOR-3TC-TDF in another phase 3 clinical trial, DRIVE-SHIFT ([@B5]).

DOR may be an effective alternative for patients who do not tolerate efavirenz, a commonly used NNRTI that is included in many HIV-1 treatment regimens. The predominant route of elimination for DOR is oxidative metabolism mediated primarily by cytochrome P450 3A4 (CYP3A4) ([@B6]). Because efavirenz is a moderate inducer of CYP3A, a drug-drug interaction study was previously conducted in healthy adults to assess the pharmacokinetics of both drugs following a switch from efavirenz to DOR ([@B7]). In that study, plasma concentrations of DOR on day 1 and day 14 after a switch from efavirenz were lower than those determined in the absence of prior efavirenz treatment. The DOR trough concentration reached the *in vitro*-based target for inhibition of wild-type HIV-1 (78 nM) on day 2 after efavirenz cessation, while efavirenz was present at therapeutic concentrations (\>1,000 ng/ml) until day 4. To understand the clinical relevance of this interaction, we conducted *post hoc* analyses of DOR plasma levels and the maintenance of viral suppression in participants who switched from an efavirenz-based regimen to DOR-3TC-TDF in the DRIVE-SHIFT clinical trial.

Study design and participants. {#s1.1}
------------------------------

The DRIVE-SHIFT study was an open-label, active-control, noninferiority trial in adults with HIV-1 who had experienced virological suppression for at least 6 months with two nucleoside reverse transcriptase inhibitors (NRTIs) plus a boosted protease inhibitor, boosted elvitegravir, or an NNRTI ([@B5]). The protocol was approved by the independent ethics committee for each study site, and all participants provided written informed consent before any study procedures were performed. Participants were randomly assigned, in a 2:1 ratio, to switch to once-daily DOR-3TC-TDF on day 1 (immediate switch group \[ISG\]) or to continue their current therapy and to switch to DOR-3TC-TDF at week 24 (delayed switch group \[DSG\]). Of the 670 participants who entered the trial, 114 (17%) were receiving an efavirenz-based regimen, and 556 (83%) were receiving two NRTIs with a boosted protease inhibitor, boosted elvitegravir, nevirapine, or rilpivirine. Baseline characteristics of these two groups were generally similar ([Table 1](#T1){ref-type="table"}).

###### 

Baseline demographic and clinical characteristics

  Characteristic                                      Previous efavirenz regimen (*n* = 114)   Other previous regimen (*n* = 556)[^*a*^](#T1F1){ref-type="table-fn"}
  --------------------------------------------------- ---------------------------------------- -----------------------------------------------------------------------
  Age (median \[range\]) (yr)                         46 (24--71)                              42 (21--71)
  Male (no. \[%\])                                    98 (86.0)                                468 (84.2)
  Race/ethnicity (no. \[%\])                                                                   
      White                                           78 (68.4)                                434 (78.1)
      Black or African American                       18 (15.8)                                72 (12.9)
      Asian                                           7 (6.1)                                  18 (3.2)
      Multiracial                                     6 (5.3)                                  29 (5.2)
      Other race[^*b*^](#T1F2){ref-type="table-fn"}   5 (4.4)                                  3 (0.5)
      Hispanic or Latino                              34 (29.8)                                110 (19.8)
  Region (no. \[%\])                                                                           
      Asia/Pacific region                             13 (11.4)                                18 (3.2)
      Europe                                          52 (45.6)                                353 (63.5)
      Latin America                                   18 (15.8)                                55 (9.9)
      North America                                   31 (27.2)                                130 (23.4)
  CD4^+^ T-cell count                                                                          
      Median (range) (cells/mm^3^)                    633 (184--1711)                          626.5 (82--1928)
      No. (%) with \<200 cells/mm^3^                  1 (0.9)                                  16 (2.9)
      No. (%) with ≥200 cells/mm^3^                   112 (98.2)                               530 (95.3)
  Duration of prior regimen                                                                    
      Median (range) (mo)                             65.1 (7.0--264.9)                        46.9 (6.9--217.6)
      No. (%) with duration of ≥12 mo                 107 (93.9)                               525 (94.4)
  History of AIDS (no. \[%\])                         20 (17.5)                                95 (17.1)
  Hepatitis B and/or C positive (no. \[%\])           3 (2.6)                                  20 (3.6)
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Other previous regimens included two NRTIs with nevirapine, rilpivirine, boosted elvitegravir, or a boosted protease inhibitor (atazanavir, darunavir, or lopinavir).

Other race included American Indian and Alaska Native.

Pharmacokinetics. {#s1.2}
-----------------

DOR plasma concentrations were measured for the 447 participants who switched to DOR-3TC-TDF on day 1; the previous antiretroviral regimen included efavirenz for 78 of those participants. Plasma samples for determination of DOR concentrations were collected before dosing at weeks 4, 24, and 48. DOR plasma concentrations were determined by Q^2^ Solutions (Morrisville, NC), using reverse-phase ultraperformance liquid chromatography with tandem mass spectrometric detection (lower limit of quantification, 1.00 ng/ml) ([@B8]).

Plasma concentrations at week 4 were stratified according to the pretrial regimen (efavirenz based versus other) and summarized according to nominal sample time ([Fig. 1](#F1){ref-type="fig"}). At week 4, predose plasma concentrations of DOR in participants who switched from an efavirenz-based regimen were consistent with those in participants who switched from another baseline regimen. Since the actual sampling times varied depending on when the participant arrived at the study site, DOR concentrations at week 4 were also plotted against the actual times since the last dose ([Fig. 2](#F2){ref-type="fig"}). The concentration profiles were similar between the two groups, supporting the comparison based on nominal times.

![DOR plasma concentrations collected at study week 4 (before dosing) according to the baseline regimen (efavirenz versus other) in the ISG. The boxplot was overlaid with observed data points. Boxes denote 25th, 50th, and 75th percentiles, and the whiskers denote 1.5 times the interquartile range of distribution of predose samples.](AAC.01298-19-f0001){#F1}

![Individual plasma concentrations of DOR versus the actual time since the last dose at study week 4 in the ISG.](AAC.01298-19-f0002){#F2}

Clinical efficacy. {#s1.3}
------------------

The primary efficacy endpoint in the DRIVE-SHIFT study was the proportion of participants with \<50 copies/ml HIV-1 RNA at the primary time points of week 48 for the ISG and week 24 for the DSG, with the secondary time point of week 24 for both groups. The proportion of participants with ≥50 copies/ml HIV-1 RNA was a secondary endpoint and was also assessed at the primary and secondary time points. The efficacy analyses used the FDA Snapshot approach, which counts all missing data as failures regardless of the reason. The differences between treatment groups and the associated 95% confidence intervals (CIs) were calculated using the stratum-adjusted Mantel-Haenszel method.

The antiretroviral efficacy of DOR-3TC-TDF was similar for ISG participants who switched from an efavirenz-based regimen and those who switched from another baseline regimen ([Table 2](#T2){ref-type="table"}). At weeks 24 and 48, \<50 copies/ml HIV-1 RNA was achieved in 97.4% and 93.6%, respectively, of the ISG participants who switched from an efavirenz-based regimen, compared with 93.0% and 90.2% of those who switched from another baseline regimen. Regarding the secondary endpoint, the proportions of participants with ≥50 copies/ml HIV-1 RNA at weeks 24 and 48 were 1.3% and 0.0%, respectively, of the ISG participants who switched from efavirenz, compared with 1.9% and 1.9% of those who switched from another baseline regimen. Only 1 ISG participant who switched from efavirenz had ≥50 copies/ml HIV-1 RNA at week 24, with a reported value of 51 copies/ml; the participant had \<50 copies/ml HIV-1 RNA at all other time points in the study, including week 48. Only 1 participant with ≥50 copies/ml HIV-1 RNA had sufficient virus for resistance testing. That participant had switched from a non-efavirenz-based regimen and was discontinued from the study at week 36 due to lack of efficacy. No DOR resistance mutations were identified in that participant.

###### 

Efficacy outcomes (FDA Snapshot approach)

  Group[^*a*^](#T2F1){ref-type="table-fn"}                     No./total no. (% \[95% CI\])      Difference (% \[95% CI\])         
  ------------------------------------------------------------ --------------------------------- --------------------------------- ---------------------
  \<50 copies/ml HIV-1 RNA                                                                                                         
      Week 24                                                                                                                      
          EFV                                                  76/78 (97.4 \[91.0 to 99.7\])     36/36 (100 \[90.3 to 100\])       −2.6 (−8.0 to 2.9)
          Non-EFV                                              343/369 (93.0 \[89.8 to 95.3\])   175/187 (93.6 \[89.1 to 96.6\])   −0.8 (−5.4 to 3.8)
      ISG week 48 vs DSG week 24                                                                                                   
          EFV                                                  73/78 (93.6 \[85.7 to 97.9\])     36/36 (100 \[90.3 to 100\])       −6.4 (−13.3 to 0.4)
          Non-EFV                                              333/369 (90.2 \[86.7 to 93.1\])   175/187 (93.6 \[89.1 to 96.6\])   −3.3 (−8.1 to 1.5)
  ≥50 copies/ml HIV-1 RNA[^*b*^](#T2F2){ref-type="table-fn"}                                                                       
      Week 24                                                                                                                      
          EFV                                                  1/78 (1.3 \[0.0 to 6.9\])         0/36 (0.0 \[0.0 to 9.7\])         1.3 (−3.6 to 6.2)
          Non-EFV                                              7/369 (1.9 \[0.8 to 3.9\])        4/187 (2.1 \[0.6 to 5.4\])        −0.1 (−3.0 to 2.7)
      ISG week 48 vs DSG week 24                                                                                                   
          EFV                                                  0/78 (0.0 \[0.0 to 4.6\])         0/36 (0.0 \[0.0 to 9.7\])         0.0 (−4.2 to 4.2)
          Non-EFV                                              7/369 (1.9 \[0.8 to 3.9\])        4/187 (2.1 \[0.6 to 5.4\])        −0.2 (−3.1 to 2.6)
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EFV, efavirenz.

Included participants who changed any component of background therapy to a new drug class, background components that were not permitted according to the protocol, or any background drug in the regimen because of lack of efficacy (perceived or documented) before study week 24, participants who discontinued the study drug or the study before study week 48 because of lack or loss of efficacy, and participants with ≥50 copies/ml HIV-1 RNA in the time window.

These *post hoc* analyses of data from the phase 3 DRIVE-SHIFT trial showed that plasma levels of DOR after 4 weeks of treatment with DOR-3TC-TDF were not different for participants who switched from an efavirenz-based regimen and those who switched from a protease inhibitor, elvitegravir, or another NNRTI-based regimen. Because DOR plasma concentrations were not measured until 4 weeks after the initiation of therapy, our analyses did not address whether DOR exposure was reduced in the immediate period after the switch from efavirenz, as was observed in the phase 1 drug interaction study ([@B6]). Our analyses also showed that the antiretroviral efficacy of DOR at week 24 and week 48 was similar for participants who switched from an efavirenz-based regimen and those who switched from another baseline regimen. Thus, the antiretroviral efficacy of DOR was not adversely affected by prior treatment with efavirenz.
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